Mydecine Innovations has reported a positive pre-investigational new drug (IND) meeting with America’s Food and Drug Administration (FDA) regarding its psychedelic compound for smoking cessation.
PharmaDrug has generated data showing that DMT-analogues could provide a new treatment for primary open angle glaucoma.
A recent study testing the impact of microdosing LSD has suggested the practice has no therapeutic or cognitive effects.
A new collaboration will investigate the efficacy of EVM-101, a first-generation psychedelic treatment, for the treatment of Cancer Related Distress (CRD).
New results have demonstrated treating major depressive disorder (MDD) with psilocybin-assisted psychotherapy is effective for up to a year in some patients.
Some patients hospitalised with severe suicidal thoughts could benefit from ketamine treatment.
A group of scientists have reported findings that provide a foundation for the structure-based design of safe and effective non-hallucinogenic, rapid-acting antidepressants.
A Phase I clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of DMT will further research into the compound’s therapeutic potential.
A new narrative review of systematic evidence has been published by leading researchers at Drug Science to get the facts on the adverse effects of classic...
An amanita muscaria extract – AME-1 – has been shown to hold anti-inflammatory properties in a Psyched Wellness study.